How to reduce portfolio risk using structured products

STRUCTURED PRODUCTS

clock

Structured products offer distinct advantages for actively managed portfolios. Paul Burgin explains why

Advisers and discretionary managers traditionally placed structured products in their ‘other’ allocation buckets but this may be changing. Many now consider structured products as more bond-like solutions. “At the outset, a large part of the product is effectively a bond,” says Marc Chamberlain, executive director of provider Morgan Stanley. He believes structured products can be used to offset risks in active equity management. A typical example involves UK equities. Chamberlain suggests advisers consider diversifying their exposure to active managers, and therefore manage risk, b...

To continue reading this article...

Join Investment Week for free

  • Unlimited access to real-time news, analysis and opinion from the investment industry, including the Sustainable Hub covering fund news from the ESG space
  • Get ahead of regulatory and technological changes affecting fund management
  • Important and breaking news stories selected by the editors delivered straight to your inbox each day
  • Weekly members-only newsletter with exclusive opinion pieces from leading industry experts
  • Be the first to hear about our extensive events schedule and awards programmes

Join now

 

Already an Investment Week
member?

Login

More on Specialist

While thematic funds offer diversification and a specialist knowledge base, investors must also consider the sensitivity to real bond yields inherent in these funds.

Deep Dive: Thematics offer diversification but investors must consider bond sensitivity

‘Dedicated specialists’

James Baxter-Derrington
clock 06 April 2023 • 4 min read
Deal volumes fell last year as rising interest rates brought the end of cheap money

European private equity yet to spend €270bn worth of capital

Deployment of capital expected

Kathleen Gallagher
clock 04 January 2023 • 1 min read
Ali H. Munawar, CEO of Pledge Therapeutics

Early-stage biopharma: An opportunity for strategic investment

Disproportionately smaller investment

Ali H. Munawar
clock 10 August 2022 • 4 min read
Trustpilot